Artelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic Pain

Professor Saoirse O’Sullivan, vice president of translational sciences at Artelo Biosciences, Inc. ARTL, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 33^rd International Cannabinoid Research Society symposium in Toronto, Ontario, Canada.

“Growing evidence of ART26.12’s activity on neuropathic pain caused by various chemotherapies or diabetes further substantiates developing our potent and novel FABP5 inhibitor as an innovative new treatment for painful neuropathies,” stated Gregory D. Gorgas, Artelo’s president and CEO. There are very limited therapeutic options currently available and these existing treatments are often associated with a significant and undesirable side effect profile. According to Coherent Market Insights, the global neuropathic pain market is estimated to be valued at $7.6 billion. “We are making substantial progress in advancing this important program towards the clinic and are looking forward to receiving pre-IND meeting minutes from the FDA during the third quarter of this year, which will mark a substantial milestone for ART26.12,” added Gorgas.

“ART26.12 continues to demonstrate a positive effect in numerous animal models of painful neuropathies, specifically chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy,” stated O’Sullivan. “We were pleased to present new data with paclitaxel that confirms a previous study with oxaliplatin-induced CIPN which suggests a common mechanism of action of ART26.12 that is capable of preventing allodynia from both taxane- and platinum-based agents, the two most common causes of CIPN,” continued O’Sullivan “In another animal study, orally administered ART26.12 demonstrated not only a desirable drug profile, but impotantly also reduced mechanical hypersensitivity in painful diabetic neuropathy. Based on these results, we are highly encouraged by the potential of ART26.12 for the countless patients suffering from this often excruciating and debilitating condition.”

About ART26.12
Fatty acid binding proteins are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. Various inhibitors of FABPs may be particularly useful for the treatment of specific cancers, neuropathic and nociceptive pain, and anxiety disorders. ART26.12, Artelo’s lead FABP inhibitor compound, is a selective inhibitor of FABP5.

Photo by Louis Reed on Unsplash

Related News

Artelo Biosciences Presents Groundbreaking Research At Annual CBD Symposium In Canada

Artelo Enters Next Phase Of Evaluation Of Its Cannabinoid Receptor Targeting Drug For The Treatment Of Cancer-Related Anorexia And Weight Loss

Why ORIC Pharmaceuticals Shares Are Trading Higher By Around 46%; Here Are 27 Stocks Moving Premarket